This module covers the pathogenesis, treatment, and prevention of anaphylaxis.

Price: $20 Members, $30 Nonmembers

Release Date: June 1, 2015
Expiration Date: May 31, 2018

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity is not supported by commercial interests. 

Target Audience

•    Practicing allergists/immunologists and other physicians who care for allergy patients
•    Fellows in allergy/immunology training programs
•    Allied health professionals in the field of allergy and immunology

Learning Objectives

At the completion of this module, participants should be able to:
•     Discuss recent advances in the treatment of anaphylaxis
•     Explain recent theories regarding the pathogenesis of anaphylactic reactions
•     Prevent episodes of anaphylaxis 

Core Competencies
The following core competencies will be addressed:
•     Patient Care
•     Medical Knowledge 

Additional information

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Phillip L. Lieberman, MD
Consultant/Advisory Board: Genentech, Meda, Mylan, Teva
Speaker: Genentech, Meda, Merck, Mylan, Teva

David A. Khan, MD
Speaker, Honorarium: Baxter, Genentech

Charles J. Siegel, MD
Consultant/Advisory Board: Meda, Teva
Speaker, Honorarium: Alcon, Meda, Teva

Education Staff/Committee/Reviewers have no financial relationships to disclose, except as may be listed above.

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

Phillip L. Lieberman, MD
Clinical Professor Medicine and Pediatrics
Department of Internal Medicine/Pediatrics
Division of Allergy and Immunology 
University of Tennessee College of Medicine
Memphis, TN

Planning Committee
Phillip L. Lieberman, MD
David A. Khan, MD
Charles J. Siegel, MD 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance


Please login or create an account to take this course.